RNA toxicity encompasses a range of pathological mechanisms where abnormal RNA molecules, toxic gain-of-function from mutant proteins, or disruption of RNA metabolism lead to neuronal dysfunction and death. This pathway is particularly prominent in amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and several spinocerebellar ataxias[1].
| Protein/RNA | Function | Disease Association |
|---|---|---|
| C9orf72 | Hexanucleotide repeat expansion | ALS/FTD |
| TDP-43 | RNA-binding protein, splicing | ALS, FTD, AD |
| FUS | RNA-binding protein, transport | ALS, FTD |
| TIA1 | Stress granule formation | ALS, FTD |
| RAN Translation | Repeat-associated non-AUG translation | C9orf72 |
| Ataxins | Polyglutamine expansion | SCA1, 2, 3, 6, 7, 17 |
The GGGGCC hexanucleotide repeat expansion in the first intron of the C9orf72 gene is the most common genetic cause of familial ALS and FTD[2]. This mutation leads to disease through three primary mechanisms:
RNA Toxicity: The expanded repeat RNA forms toxic RNA foci that sequester essential RNA-binding proteins, disrupting normal RNA metabolism. These foci accumulate in the nucleus and cytoplasm, interfering with splicing, transport, and translation of critical neuronal mRNAs.
Dipeptide Repeat Proteins (DPRs): Repeat-associated non-AUG (RAN) translation produces five dipeptide repeat proteins (poly-GA, poly-GR, poly-PR, poly-PA, poly-GP) from both sense and antisense transcripts[3]. These DPRs are aggregation-prone and cause toxicity through multiple mechanisms including:
Loss of Function: The expansion reduces C9orf72 expression, impairing normal functions in endolysosomal trafficking and autophagy[2:1]. This loss-of-function may contribute to disease pathogenesis.
TDP-43 (TAR DNA-binding protein 43) is an RNA-binding protein that is pathologically aggregated in most ALS cases and approximately 50% of FTD cases[4]. Key mechanisms include:
Cytoplasmic Aggregation: Pathological TDP-43 forms cytoplasmic inclusions that sequester normal TDP-43 and other RNA-binding proteins, disrupting RNA metabolism.
Nuclear Loss: TDP-43 nuclear clearance leads to loss of its normal splicing and RNA processing functions, resulting in aberrant splicing of target mRNAs.
Stress Granule Dysregulation: TDP-43 is recruited to stress granules during cellular stress, where its persistent aggregation may lead to toxic inclusions[5].
Mutations in the FUS gene cause a distinct form of ALS with early onset and rapid progression[6]. FUS pathology involves:
Cytoplasmic Mislocalization: FUS mutations impair its nuclear localization signal (NLS), leading to cytoplasmic accumulation and aggregation.
Stress Granule Abnormalities: FUS-positive stress granules are more prone to solidify into irreversible aggregates, disrupting translation and RNA metabolism.
DNA Damage Response: FUS is involved in DNA damage repair, and its dysfunction leads to genomic instability in neurons.
One of the central mechanisms in RNA toxicity-mediated neurodegeneration is disruption of nucleocytoplasmic transport[12]. Multiple disease mechanisms converge on this pathway:
Nuclear Pore Complex Integrity: DPRs, FUS aggregates, and TDP-43 inclusions can directly damage nuclear pore complex components.
Importin Dysfunction: RNA-binding protein aggregates sequester importins, impairing nuclear import of essential proteins.
Exportin Disruption: RAN translation products interfere with exportin-mediated nucleocytoplasmic transport.
Consequences: This leads to nuclear accumulation of cytoplasmic proteins, decreased nuclear import of transcription factors and RNA processing proteins, and eventual cellular dysfunction and death.
Stress granules are membrane-less organelles that form in response to cellular stress and dissolve when stress resolves[5:1]. In neurodegeneration, stress granules become pathological:
Persistent Granules: In disease states, stress granules fail to dissolve properly, becoming stable inclusions.
Sequestration of Essential Proteins: Pathological stress granules sequester TIA1, G3BP1, and other RNA-binding proteins, disrupting normal RNA metabolism.
Transition to Aggregation: Persistent stress granules can transition into irreversible protein aggregates characteristic of neurodegeneration.
RNA foci represent another pathological hallmark of repeat expansion diseases[13]. These nuclear or cytoplasmic accumulations of expanded repeat RNA:
Protein Sequestration: RNA foci sequester essential splicing factors, including TDP-43, hnRNPs, and SRSF proteins.
Splicing Dysregulation: Loss of splicing factors leads to aberrant splicing of multiple neuronal transcripts.
Toxic Gain-of-Function: The foci themselves may directly interfere with nuclear processes.
Repeat-associated non-AUG (RAN) translation produces proteins from expanded repeats without a start codon[14]. This mechanism:
Bidirectional Translation: RAN translation occurs in both sense and antisense directions, producing multiple toxic proteins.
Aggregation-Prone Products: DPRs are highly aggregation-prone, forming intracellular inclusions.
Cellular Toxicity: Each DPR has distinct toxic properties affecting different cellular pathways.
Recent research has revealed that C9orf72 repeat expansions disrupt nuclear speckle integrity, leading to widespread RNA splicing dysregulation[15]. Nuclear speckles are membraneless organelles that serve as hubs for RNA processing and splicing factor storage. The expanded GGGGCC repeats:
The exocyst complex component EXOC2 has been identified as a critical regulator of C9orf72 repeat toxicity[16]. EXOC2:
Poly-GR dipeptide repeats have been shown to impair translation elongation and induce ribotoxic stress through p38 MAPK activation[17]. This mechanism:
The hexanucleotide repeat RNA forms tetrameric G-quadruplex structures that are toxic in ALS/FTD[18]. These structures:
Antisense oligonucleotides (ASOs) represent the most advanced therapeutic approach for RNA toxicity disorders[19]:
Mechanism: ASOs bind to target RNA and promote its degradation or modulate splicing.
Clinical Success: Tofersen (BIIB055) has received regulatory approval for SOD1-associated ALS.
C9orf72-Targeted ASOs: Multiple ASOs targeting C9orf72 expansion RNA are in clinical trials (BIIB060, WVE-004).
Challenges: Efficient delivery to the CNS, off-target effects, and patient selection remain active areas of investigation.
Several small molecule approaches are in development:
RNA-Binding Protein Modulators: Compounds that disrupt toxic RNA-protein interactions.
Stress Granule Modulators: Drugs promoting stress granule dissolution or preventing their pathological transition.
RAN Translation Inhibitors: Compounds reducing DPR production from expanded repeats.
Viral vector-mediated gene delivery offers potential for long-term treatment:
AAV-Mediated Delivery: AAV vectors can deliver therapeutic genes to neurons.
Gene Silencing: shRNA or siRNA approaches targeting mutant allele expression.
Gene Replacement: Delivering healthy gene copies for loss-of-function mechanisms.
Recent advances have identified new therapeutic targets:
Artificial MicroRNA Approach: Artificial miRNAs can suppress C9orf72 variants and decrease toxic DPR production in vivo, representing a promising gene therapy strategy (PMID: 37752346).
G-Quadruplex Targeting: Small molecules that bind to the G-quadruplex structures formed by expanded C9orf72 repeats can reduce RNA toxicity. Triplex-like antisense RNA ligands also show promise.
p38 Inhibition: Poly-GR-induced ribotoxic stress can be ameliorated through p38 kinase inhibition, representing a downstream therapeutic target.
ZAKalpha Targeting: Knockdown of ZAKalpha kinase is neuroprotective against poly-GR toxicity, providing another target.
| Treatment | Target | Status | Indication |
|---|---|---|---|
| Tofersen | SOD1 | Approved | ALS |
| BIIB060 | C9orf72 | Phase 1 | ALS/FTD |
| WVE-004 | C9orf72 | Phase 1 | ALS/FTD |
| ASO for ATXN2 | ATXN2 | Phase 1 | SCA2 |
| Reldesemtide | SOD1 | Phase 3 | ALS |
| Nobutra | TDP-43 | Preclinical | ALS/FTD |
Progressive muscle weakness, atrophy, fasciculations, and spasticity characterize ALS[21]. Upper motor neuron signs (brisk reflexes, spasticity) and lower motor neuron signs (weakness, atrophy, fasciculations) coexist.
Frontotemporal dementia presents with progressive changes in personality, behavior, and language[22]. Behavioral variant FTD and primary progressive aphasia are the main subtypes.
Awareness El Escorial Criteria (modified):
Fibrinogen exacerbates α-synuclein aggregation and mitochondrial dysfunction via alpha5beta3 integrin in Parkinson's disease. 2026. ↩︎
" C9orf72 in ALS/FTD: From gain-of-function to loss-of-function". 2019. ↩︎ ↩︎
Stress granule dynamics in neurodegenerative disease. 2024. ↩︎ ↩︎
Ginsenoside compound K inhibited the gelation of GGGGCC repeats and regulated co-aggregation with arginine-rich poly-dipeptides in C9orf72-related ALS. 2026. ↩︎
The DNA/RNA autophagy protein SIDT2 as a novel neuropathological hallmark in Huntington disease. 2026. ↩︎
BTK inhibition suppresses neuroinflammation and neurodegeneration in amyotrophic lateral sclerosis. 2026. ↩︎
" Spinocerebellar ataxia type 2: disease mechanisms and therapeutics". 2024. ↩︎
Breaking β-sheets in FUS prion-like domain preserves phase separation and function but prevents aggregation and toxicity. 2026. ↩︎
Repeat-associated non-AUG translation in neurodegenerative disease. 2022. ↩︎
Disruption of nuclear speckle integrity dysregulates RNA splicing in C9ORF72-FTD/ALS. 2024. ↩︎
EXOC2 regulates toxicity of expanded GGGGCC repeats in C9ORF72-ALS/FTD. 2024. ↩︎
Poly-GR repeats impair translation elongation and induce ribotoxic stress. 2024. ↩︎
Crystal structure of tetrameric RNA G-quadruplex in C9orf72 ALS/FTD. 2024. ↩︎
Biomarkers in ALS and FTD. 2024. ↩︎
" Amyotrophic lateral sclerosis: clinical features and pathogenesis". 2023. ↩︎
Frontotemporal dementia: molecular mechanisms and therapeutic targets. 2024. ↩︎